RSS   Newsletter   Contact   Advertise with us

AstraZeneca sells anaesthetic rights to Aspen

Staff Writer | September 1, 2016
AstraZeneca has completed its commercialisation agreement with Aspen Global Incorporated, for rights to its global anaesthetics portfolio outside the U.S.
Pharma   AstraZeneca sold seven established medicines
AstraZeneca said the agreement covers seven established medicines - Diprivan, EMLA, Xylocaine, Marcaine, Naropin, Carbocaine and Citanest.

"As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment - to be recognised in the third quarter of 2016 - along with all future milestone and royalty payments, will be reported as externalisation revenue in the company's financial statements," AstraZeneva's board said in a statement.

The externalisation came after AstraZeneca was found paying Chinese medical experts large "speaking fees" to share their knowledge at events which never took place.